摘要
目的探讨E-cad、β-cat和Ki-67与膀胱癌病理分级和临床分期之间的关系。方法应用免疫组化技术检测73例膀胱癌标本E-cad、β-cat和Ki-67的表达水平,进行分析上述指标与膀胱癌病理分级和临床分期的关系以及E-cad和Ki-67联合检测与膀胱癌病理分级和临床分期的关系。结果①E-cad、β-cat的表达强度与膀胱癌的病理分级和临床分期负相关,Ki-67的表达强度与膀胱癌的病理分级和临床分期正相关;②膀胱癌E-cad和Ki-67的异常表达存在相关性,E-cad和Ki-67双异常表达与膀胱癌的病理分级和临床分期均相关。结论膀胱癌存在着E-cad、β-cat表达的下调和Ki-67表达的上调,三者表达异常均与膀胱癌的病理分级和临床分期有关。E-cad和Ki-67双异常表达的膀胱癌病理分级和临床分期均较高,E-cad表达与Ki-67表达呈负相关,同时检测E-cad和Ki-67有助于对膀胱癌病理分级和临床分期的判断。
Objective To investigate the possible relationship between E-cad, β-cat and Ki-67 expression in bladder transitional cell carcinoma (BTCC) and its pathological grade and clinical stage. Methods An immunohistochemical method was used to examine the expression of E-cad, β-cat and Ki-67 in 73 paraffin-embedded urinary bladder transitional cell carcinoma specimens, then the aboverelationship was analysed. Results The different expressions of E-cad, β-cat and Ki-67 were statistically significant (all the P values were 〈0.05). There was close correlation between E-cad and ki- 67 expression and correlation was statistically significant. Conclusion The expression of E-cad, β-cat are significant lower and Ki-67 is significant higher in BTCC. The aberrant expression of E-cad, β-cat and ki-67 is related to the pathological grade and clinical stage of BTCC. The expressions of them are in the characteristic of heterogeneity all. E-cad expression is correlated with ki-67 expression negatively in BTCC.
出处
《实用医药杂志》
2008年第8期900-902,共3页
Practical Journal of Medicine & Pharmacy